GlobeNewswire Inc.T3·5mo ago
FBLG FibroBiologics, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
FBLG
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 15
- List Date
- 2024-01-31
- CIK
- 0001958777
- Next Earnings
- 2026-10-30
- EPS Forecast
- ($0.63) (1 est.)
- Headquarters
- Houston, TX
- Homepage
- https://www.fibrobiologics.com
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | 0.00% | -18.89% | 38.31% | 6.47% |
| Feb | -25.37% | -22.22% | 15.83% | -10.59% |
| Mar | -16.85% | -21.40% | -84.27% | -40.84% |
| Apr | -17.35% | 30.23% | -0.75% | 4.04% |
| May | 53.59% | -28.48% | -20.55% | 1.52% |
| Jun | -56.23% | -18.46% | -15.38% | -30.02% |
| Jul | 30.25% | 6.06% | -23.41% | 4.30% |
| Aug | -67.79% | -9.02% | 117.58% | 13.59% |
| Sep | 89.57% | -12.10% | -38.39% | 13.03% |
| Oct | 4.14% | -24.81% | -22.00%* | -14.22% |
| Nov | -17.61% | -30.56% | -- | -24.09% |
| Dec | -26.20% | -13.83% | -- | -20.02% |
| Total | -82.64% | -85.63% | -86.53% | -84.93% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.07
SMA 50: $1.32
SMA 200: $2.50
Current: $0.94
EMA 12: $1.01
EMA 26: $1.11
MACD: -0.1039 | Signal: -0.0009
BEARISH
ADX (14): 22.61
WEAK TREND
+DI: 23.53
−DI: 25.96
Momentum Oscillators
RSI (14): 35.51
NEUTRAL
Stoch %K: 24.74
Stoch %D: 26.88
Williams %R: -83.64
Volume & Volatility
BB Upper: $1.32
BB Lower: $0.82
NEUTRAL
OBV: -7,981,922
Vol SMA 20: 148,792
Vol ROC: 3.01%
ATR: $0.12
True Range: $0.06
HV 20: 72.9%
HV 30: 66.6%
HV 60: 106.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is my comprehensive stock analysis report for FBLG:
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 6/10)
Key Drivers: Negative technical signals, high correlation with market, and recent news sentiment aligning with bearish momentum.
Primary Risks: Continued downtrend, potential reversal of recent upward movement.
Investment Thesis: FBLG's recent price increase is likely to be a short-term phenomenon, driven by positive news headlines. However, the stock's underlying fundamentals are weak, and it is more likely to continue trending downward than upward.
Recent News Sentiment Impact: Positive news sentiment has contributed to the recent price increase, but this could quickly turn negative if earnings or other catalysts disappoint expectations.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bearish
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bearish
Support/Resistance Levels: $1.39 (SMA 20), $1.05 (SMA 50), and $0.75 (Bollinger Bands Lower)
Momentum Signals:
- RSI interpretation: Oversold (<30)
- MACD signal: Bullish momentum
- Bollinger Bands position: Mean reversion
Volume Analysis: Volume has been decreasing, suggesting institutional selling.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines from Q1 2026 financial results and corporate update, as well as the overall trend of psoriasis clinical trial pipeline growth.
Sentiment Assessment: Overall sentiment is POSITIVE (based on recent news headlines).
Catalyst Identification: Upcoming earnings release could provide a catalyst for further price movement.
Market Narrative: Recent positive news has driven the stock price upward, but this may not be sustainable in the long term.
Risk & Volatility Assessment
Beta Interpretation: Low risk relative to market (beta = 0.30).
Volatility Regime: Current volatility is low compared to historical levels.
Options Market Signals: No options data available for analysis.
Downside Protection: Support level at $1.05 (SMA 50) could provide a cushion against further price declines.
Market Context & Positioning
Sector Performance: FBLG's sector is experiencing growth, but the stock itself has not participated in this trend.
Institutional Activity: Decreasing volume suggests institutional selling.
Correlation Analysis: High correlation with market (0.03), which could lead to similar price movements.
Relative Valuation: FBLG is trading below its historical average and relative to its sector peers.
Key Levels & Action Items
Critical Price Levels:
- Support at $1.05 (SMA 50)
- Resistance at $2.03 (Bollinger Bands Upper)
Breakout/Breakdown Levels:
- Potential breakdown below $0.75 (Bollinger Bands Lower)
- Potential breakout above $2.03 (Bollinger Bands Upper)
Time-Sensitive Catalysts: Upcoming earnings release could provide a catalyst for further price movement.
Risk Management: Stop-loss levels should be set at $1.05 (SMA 50) to limit potential losses.
I hope this analysis meets the requirements! Let me know if you have any questions or need further clarification on any of the points I've made.
Generated
News
All FBLG news →
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·6mo ago
BenzingaT3·7mo ago
BenzingaT3·11mo ago
GlobeNewswire Inc.T3·11mo ago
GlobeNewswire Inc.T3·19mo ago
GlobeNewswire Inc.T3·19mo ago
GlobeNewswire Inc.T3·20mo ago
GlobeNewswire Inc.T3·20mo ago
Showing 1–10 of 26
Page 1 of 3
FBLG Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.0952
Alpha: -132.53%
Correlation: 0.0093
R-Squared: 0.0%
Stock Volatility: 130.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
FBLG Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
FBLG Insider Trading (Form 4)
Latest: 2026-09-15Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Hamid Khoja | Chief Scientific Officer | Award (A) | +298,508 | $1.68 | $500.0K | EDGAR |
| 2026-06-23 | Matthew Link | Director | Grant (A) | +30,803 opt | — | EDGAR | |
| 2026-06-23 | Victoria Ninon Olivia Niklas | Director | Grant (A) | +30,803 opt | — | EDGAR | |
| 2026-06-23 | Robert E. Hoffman | Director | Grant (A) | +30,803 opt | — | EDGAR | |
| 2026-06-23 | Richard C. Cilento Jr. | Director | Grant (A) | +30,803 opt | — | EDGAR | |
| 2026-05-04 | Pete O'Heeron | CHIEF EXECUTIVE OFFICER | Grant (A) | +92,410 opt | — | EDGAR | |
| 2026-05-04 | Jason Davis | Chief Financial Officer | Grant (A) | +61,607 opt | — | EDGAR | |
| 2026-05-04 | Ruben A Garcia | General Counsel | Grant (A) | +61,607 opt | — | EDGAR | |
| 2026-05-04 | Hamid Khoja | Chief Scientific Officer | Grant (A) | +61,607 opt | — | EDGAR | |
| 2026-03-05 | Hamid Khoja | Chief Scientific Officer | Buy (P) | +30,000 | $0.38 | $11.4K | EDGAR |
| 2026-03-04 | Pete O'Heeron | CHIEF EXECUTIVE OFFICER | Buy (P) | +51,500 | $0.38 | $19.5K | EDGAR |
| 2026-03-03 | Jason Davis | Chief Financial Officer | Buy (P) | +70,000 | $0.41 | $29.0K | EDGAR |
| 2026-03-02 | Ruben A Garcia | General Counsel | Buy (P) | +40,000 | $0.33 | $13.1K | EDGAR |
| 2025-12-12 | Ruben A Garcia | General Counsel | Buy (P) | +140,000 | $0.34 | $47.6K | EDGAR |
| 2025-06-12 | Stacy Ann Coen | Director | Grant (A) | +22,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
FBLG Insider Holdings
4 insiders · @ $0.94
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Hamid Khoja | Chief Scientific Officer | 301,571 | $283.4K | $47.2K | 7 | 2026-09-15 |
| 2 | Pete O'Heeron | CHIEF EXECUTIVE OFFICER | 297,907 | $280.0K | $35.8K | 7 | 2026-05-04 |
| 3 | Ruben A Garcia | General Counsel | 9,000 | $8.5K | $60.7K | 6 | 2026-05-04 |
| 4 | Jason Davis | Chief Financial Officer | 3,500 | $3.3K | $29.0K | 3 | 2026-05-04 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
FBLG Board & Officers
As of SEC filings through Sep 15, 2026Directors 8
- Matthew Link · since Jan 24, 2024
- Pete O'Heeron · since Jan 24, 2024
- Richard C. Cilento Jr. · since Jan 24, 2024
- Robert E. Hoffman · since Jan 24, 2024
- Stacy Ann Coen · since Jan 24, 2024
- Victoria Ninon Olivia Niklas · since Jan 24, 2024
- Kathleen Hallisey Rubins · since Jul 8, 2026
- Leigh Steinberg · since Aug 20, 2026
Officers 4
- Pete O'Heeron · Chief Executive Officer · since Jan 24, 2024
- Jason Davis · Chief Financial Officer · since Jun 9, 2025
- Hamid Khoja · Chief Scientific Officer · since Jan 24, 2024
- Ruben A Garcia · General Counsel · since Mar 1, 2024
Changes in the last 10 years (14)
| Aug 20, 2026 | Leigh Steinberg became a director |
| Jul 8, 2026 | Kathleen Hallisey Rubins became a director |
| Jun 9, 2025 | Jason Davis became Chief Financial Officer |
| Oct 25, 2024 | The company announced the departure of Mark C. Andersen as Chief Financial Officer in an SEC filing |
| Mar 1, 2024 | Ruben A Garcia became General Counsel |
| Jan 24, 2024 | Victoria Ninon Olivia Niklas became a director |
| Jan 24, 2024 | Stacy Ann Coen became a director |
| Jan 24, 2024 | Robert E. Hoffman became a director |
| Jan 24, 2024 | Richard C. Cilento Jr. became a director |
| Jan 24, 2024 | Pete O'Heeron became a director |
| Jan 24, 2024 | Pete O'Heeron became Chief Executive Officer |
| Jan 24, 2024 | Matthew Link became a director |
| Jan 24, 2024 | Mark C. Andersen became Chief Financial Officer |
| Jan 24, 2024 | Hamid Khoja became Chief Scientific Officer |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
1 ETF hold FBLG
1 shown · $82.34K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $82,339 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.